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We  have  developed  a  selection  scheme  to  generate 
nucleic acid sequences that recognize and directly inter-
nalize into mammalian cells without the aid of conven-
tional delivery methods. To demonstrate the generality 
of the technology, two independent selections with dif-
ferent  starting  pools  were  performed  against  distinct 
target cells. Each selection yielded a single highly func-
tional sequence, both of which folded into a common 
core structure. This internalization signal can be adapted 
for use as a general purpose reagent for transfection into 
a wide variety of cell types including primary cells.
Received 31 August 2011; accepted 19 November 2011; published online 
10 January 2012. doi:10.1038/mt.2011.277
IntroductIon
RNA molecules can be internalized into cells and used to deliver 
reporters and therapeutic cargoes.1–6 Aptamers that bind to cell 
surface  markers  such  as  the  cancer  marker  prostate-specific 
membrane antigen (PSMA),7 epidermal growth factor receptor 
(EGFR)8 or the viral protein gp1203,9 appear to deliver their car-
goes via endocytosis.10–13 These findings are particularly signifi-
cant given that aptamers can be readily synthesized, facilitating 
their site-specific conjugation to a variety of reporters or thera-
peutic moieties,14,15 a feat that is still difficult for antibodies and 
many other protein-based targeting agents.
The relationship between aptamer binding, uptake, and func-
tional delivery appears to be idiosyncratic. Because the mecha-
nism  is  still  poorly  understood,  we  reasoned  that  a  selection 
approach  would  be  useful  both  for  generating  superior  inter-
nalizing reagents and also for providing additional insights into 
the routes by which aptamers deliver cargoes. Selections against 
whole cells have previously been carried out,16–22 and some have 
yielded aptamers capable of being internalized by cells.20 We have 
now augmented this technology to enable the selection of nucleic 
acids that could not only recognize a cell, but also enter it. Briefly, 
a nucleic acid pool was added directly to cells, and nucleic acids 
that failed to internalize were removed by stringent nuclease treat-
ment. Total cell RNA was extracted, and internalized sequences 
were recovered by reverse transcription-PCR and transcription 
(Figure 1a). Surprisingly, when we performed selections using 
two different libraries against cell lines from two different species, 
we identified a common core motif that appears to be a general 
internalization signal for RNA. Much like the cell surface selec-
tions, it should be possible to generalize this method to many dif-
ferent cells and tissues, even in the absence of any knowledge of 
mechanism or cell surface architecture.
results
Proofing the selection method
Selections  were  initiated  with  RNA  pools  containing  2′-ribo 
purine/2′-fluoro pyrimidine (2′-fluoro-modified). This modifica-
tion renders RNA largely nuclease-resistant.21 We initially proofed 
the method with a known internalizing aptamer, the anti-PSMA 
aptamer, A97,10,15 (Figure 1b). Approximately 105 PSMA-expressing 
LnCAP cells were treated with one of four conditions:
(1) Cells were incubated with the anti-PSMA aptamer.
(2) Cells were initially treated for 10 minutes with sodium 
azide (Az), an inhibitor of oxidative phosphorylation, and 
2-deoxyglucose (dG), an inhibitor of glycolysis, to prevent 
endocytosis before addition of the aptamer.
(3) Cells  were  incubated  with  the  anti-PSMA  aptamer  fol-
lowed by treatment with nuclease to digest external bind-
ers. While the 2′-fluoro modifications rendered the RNAs 
largely resistant to cellular nucleases, we had previously 
identified  conditions  that  would  degrade  a  modified 
RNA pool. RNase T1 (which cleaves after G residues) and 
RNase A (which cleaves single-stranded RNA (ssRNA)) 
treatment led to only partial degradation of the pool, but 
Riboshredder (Rb), a commercial cocktail of nucleases, 
effectively eliminated all full-length pool RNAs (data not 
shown).
(4) Cells were pre-treated as in (1), then incubated with the 
aptamer RNA and, finally, nuclease-treated as in (3) to 
remove surface binders.
Following treatment, total cell RNA was recovered from each 
sample, reverse-transcribed with aptamer-specific primers, and 
the  number  of  aptamers  recovered  was  determined  relative  to 
a nontreated cell control. As might be expected, treatment with 
Az-dG decreased the total amount of recovered RNA. Treatment 
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with Riboshredder reduced the signal even more drastically, indi-
cating that much of the aptamer remained extracellular. However, 
some signal (approximately twofold over background) remained, 
presumably  due  to  internalization  (Figure 1b; Supplementary 
Figure  S1).  Treatment  of  the  cells  with  both  Az-dG  and  Rb 
brought the amount of RNA detected down to background levels.
A similar experiment with another internalizing RNA, the anti-
EGFR aptamer, E07, also showed that endocytosis inhibition led 
to a decrease in the amount of RNA recovered following nuclease 
treatment. In this case, the RNA was fluorescently labeled with phy-
coerythrin and analyzed by flow cytometry (Figure 1c) rather than 
being subjected to reverse transcription-PCR. As observed with 
the anti-PSMA aptamer and anti-EGFR aptamer,23 surface bound 
RNA could be destroyed by treatment with Riboshredder leading to 
a decrease in the observed fluorescence. The congruence between 
the two aptamers and the two methods strongly suggested that we 
could recover internalized RNA in the context of a selection.
Internalization selections
A test selection was initially carried out using a partially random-
ized (“doped”) library composed of ~1013 unique variants based on 
the anti-PSMA aptamer, A9. Three rounds of internalization selec-
tion were carried out against HeLa cells stably expressing PSMA 
(HeLa-PSMA) on their surfaces. In each round, the doped library 
was added directly to cells in media and incubated for 1 hour, after 
which the cells were washed several times, and nucleic acids that 
failed to internalize were further removed by nuclease treatment. 
Following this step, total cell RNA was extracted, and the inter-
nalized sequences were recovered by reverse transcription-PCR 
and subsequently transcribed back into RNA. While the Round 0 
library lacked the ability to label cells (as demonstrated by flow 
cytometry; Figure 1d), successive rounds of selection resulted in 
increased levels of binding with the Round 3 population label-
ing cells as well as the wild-type A9 aptamer. Further analysis of 
clones from Round 3 showed that 14 out of 19 variants bound 
PSMA-positive cells as well as or better than the parental aptamer 
(Supplementary Figures S2, S3, and S4).
Having shown that we could select for the internalization of a 
receptor-binding aptamer, we then wished to select for internal-
ization of sequences without regard to receptor or mechanism. We 
initiated two different internalization selections: one in which we 
targeted the common human cancer line, HeLa, and another in 
which we targeted the murine, glucose-responsive, immortalized 
β-cell line, Min6B1.
For  the  selection  against  HeLa  cells,  we  used  a  2′-fluoro- 
modified RNA aptamer pool that contained 62 random sequence 
positions  and  spanned  ~1014  unique  sequences.  For  the  first 
round, we incubated the RNA pool with 5 × 106 cells in complete 
cell culture media for 30 minutes at 37 °C. Following incubation, 
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Figure 1  selection scheme and control experiments for the identi-
fication of internalizing rnA. (a) Modification of the traditional cell 
selection protocol included a stringent nuclease step to remove surface-
bound RNA species. (b) Real-time PCR analysis to validate that selection 
conditions would identify internalizing RNA. LnCap cells were incubated 
with an anti-PSMA aptamer known to internalize into cells. The cells 
were either treated with sodium azide and deoxyglucose   (Az-dG) to 
block endocytosis, Riboshredder nuclease cocktail (Rb) to digest surface 
bound  species,  or  both  Az-dG  and  Ribo  (Az-dG/Rb).  Aptamers  were 
detected by real-time PCR analysis of total cell RNA. The reported ΔCt 
values are relative to the signal observed for the housekeeping gene 
GAPDH. (c) Flow cytometry of A431 cells incubated with the anti-EGFR 
aptamer E07 only or cells treated with E07, washed and then treated 
with Riboshredder (+RNase). Aptamers were labeled with streptavidin-
R-phycoerythrin  by  hybridization  to  a  biotinylated  oligonucleotide. 
(d) Progress of the doped A9 selection against HeLa-PSMA cells as moni-
tored by flow cytometry. The anti-PSMA aptamer (A9), Round 0 (R0) or 
Round 3 (R3) were all labeled as described in c. EGFR, epidermal growth 
factor receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 
PE, phycoerythrin; PSMA, prostate-specific membrane antigen.618  www.moleculartherapy.org  vol. 20 no. 3 mar. 2012     
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cells were washed three times with Dulbecco’s phosphate-buff-
ered  saline  (DPBS),  and  both  surface-bound  and  internalized 
RNAs were isolated by Trizol extraction. The recovered RNA was 
reverse-transcribed, PCR-amplified, and then transcribed for use 
in subsequent rounds. Following Round 2, the selection strin-
gency was increased both by trypsinizing cell surface proteins and 
by digesting surface-bound aptamers with Riboshredder before 
recovery and amplification of internalized aptamers. The overall 
selection was carried out for a total of six rounds.
Analysis  of  individual  rounds  from  the  selection  by  flow 
cytometry revealed a marked increase in the fitness of the library 
after  five  rounds  of  selection  and  amplification.  Flow  cytom-
etry assays conducted without (Figure 2a) or with Riboshredder 
  treatment (Figure 2b) suggested that a significant portion of the 
fluorescently-labeled pool was being internalized by the cells.
Selections  targeting  the  immortalized  mouse  β-cell  line, 
Min6B1, were performed similarly to those described above for 
HeLa cells. For this selection, a 2′-fluoro–modified RNA library 
encompassing 50 random positions was used as a starting point. 
Starting with ~1014 unique sequences, six initial rounds of selec-
tion were performed in which the library was incubated with cells 
for 1 hour in full media. The cells were then washed stringently 
to remove any non-bound sequences, and cells were lifted from 
the plate by treatment with trypsin and ethylenediaminetetraacetic 
acid (EDTA), but no nuclease. For Rounds 7 through 10, a nuclease 
step was added following trypsinization. For Rounds 11 and 12, 
freshly isolated mouse islets (which are composed of ~80–90% pri-
mary β-cells) were used as target cells instead of cultured Min6B1.
Flow cytometry performed with individual rounds from this 
selection indicated a progressive increase in the ability of the pop-
ulations to bind Min6B1 cells, with Rounds 11 and 12 display-
ing the highest signal (Figure 2c). Interestingly, Round 7, which 
was the first round to receive a nuclease treatment step, showed a 
marked shift in the cytometry profile, suggesting that internaliza-
tion greatly improved recovery.
Identification of an internalization motif
Sequence  analysis  of  the  Round  6  population  selected  against 
HeLa  cells  yielded  a  single,  dominant  clone  (dubbed  “Otter”) 
which comprised 48% (15/31) of the population. A second clone 
comprised an additional 26% (8/31) of the population. Two other 
clones appeared twice, and the rest of the internalizing sequences 
appeared only once (Supplementary Figure S5). Flow cytomet-
ric analysis of the individual clones revealed that Otter seemed 
to internalize readily, and, to a lesser extent, so did the “runner 
up” (Figure 2b; data not shown). As a control for surface bind-
ing, Otter was exposed to the same Riboshredder concentrations 
used in the selection experiment and was found to be completely 
degraded  after  10  minutes  of  exposure  to  the  RNase  cocktail 
(Supplementary Figure S6).
Similarly, sequence analysis of 17 clones from the Round 12 
population selected against Min6B1 cells revealed one dominant 
sequence (clone 1; c1) which encompassed 50% (8/17) of the popu-
lation (Supplementary Figure S7). We assayed this as well as nine 
other unique sequences from the Round 12 population by flow 
cytometry. In this instance, only the dominant clone, c1, showed a 
significant (~100-fold) signal increase (data not shown).
A striking feature of the selections against HeLa and Min6B1 
cells was the apparent “takeover” by a single functional sequence. 
This was far from a given; in at least one reported selection against 
whole cells, the dominant sequence (which encompassed ~50% 
of the population at the end of the selection) turned out to be 
non-functional.17  Surprisingly,  a  comparison  of  the  dominant 
sequences  from  both  selections  revealed  two  similar  regions: 
a pyrimidine rich region (Figure 2d; green) and the sequence 
5′ CUUUAUGAU (Figure 2d; red).
Generality of internalizing rnAs
The fact that a common internal motif was discovered for RNAs 
selected on two different cell lines suggested that the mechanism 
of internalization might be common to many different cell lines, 
and that therefore, the aptamers might be internalized by many 
different cell lines. In this regard, by Round 5, the aptamer popu-
lation selected against HeLa cells was also found to be taken up 
by A431 and other cells (Supplementary Figure S8), albeit with 
slightly different efficiencies. For example, the ratio of bound to 
internalized aptamer on A431 cells was ~1:1 while the ratio on 
HeLa cells was 1:0.89 (Supplementary Figure S9). Differences in 
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RNA internalization appeared to be both cell type- and aptamer-
specific, as the anti-EGFR aptamer E07 showed a reversed trend of 
uptake efficiency (1:0.22 for A431 cells and 1:0.52 for HeLa cells).
Similarly, we found that c1 was capable of staining not only 
Min6B1  cells,  but  other  mouse  lines  including  BTC3,  Bend.3 
(Supplementary Figure S10), Sol8, and C2C12 cells (data not 
shown) as well as a number of human cell lines including Jurkat, 
A549, HEK293, HeLa, PC3 (Supplementary Figure S10), and 
LnCAP cells (data not shown).
Based on previous results with other aptamers, it seemed likely 
that the common mechanism of internalization might be endo-
cytosis. When Min6B1, Bend3, and HeLa cells were treated with 
fluorescently-labeled c1 for 1 hour and then imaged by micros-
copy,  punctate  staining  was  observed,  supporting  the  notion  of 
uptake  and  localization  of  the  internalizing  sequences  within 
endosomes (Figure 3a). To investigate the mechanism of uptake 
further,  we  performed  flow  cytometry  experiments  with  Jurkat 
cells in the presence of either phenylarsine oxide, an inhibitor of 
clathrin-mediated endocytosis,24–28 or indomethacin, an inhibitor 
of caveolin-mediated endocytosis27,28 (Figure 3b). Treatment with 
phenylarsine oxide resulted in only a slight decrease in overall fluo-
rescent staining (Figure 3b; top, orange) that could be reduced to 
near background levels following treatment with RNase (Figure 3b; 
top, blue). Treatment with indomethacin had little or no effect on 
binding or observed uptake (Figure 3b; bottom). Similar results 
were observed when the same experiment was performed on HEK 
EBNA cells (Supplementary Figure S11). Taken together, these 
experiments suggest that upon receptor binding, c1 is internalized 
into mammalian cells by a clathrin-mediated endocytosis.
Minimization and exploitation of the common 
“internalization motif”
Starting from c1, we generated a series of truncations in which we 
progressively deleted both the 3′ and 5′ portions of the sequence 
(Supplementary  Figure  S12).  The  minimized  constructs  were 
initially synthesized enzymatically bearing a common 3′ constant 
region which was used for hybridization of a biotinylated oligo-
nucleotide  and  labeled  with  phycoerythrin-labeled  streptavidin. 
Constructs were then assayed for internalization by flow cytom-
etry (data not shown). A minimized variant, c1.min, that was 41 
nucleotides in length was chemically synthesized bearing a 5′ biotin 
and a 3′ inverted dT residue to enhance serum stability (Figure 4a; 
c1.min). This variant retained full activity (Figure 4b). Comparison 
of the predicted structure of c1.min with that of full-length Otter 
showed that these aptamers indeed shared the predicted common 
motif and structural core (Figure 4a). To prove that these shared 
motifs were the basis of function, we used c1.min as a model and 
designed a rational truncate of Otter, maintaining the similar core 
domains (Figure 4a; Otter.min). The minimized Otter still bound 
and was internalized into cells (Figure 4b). To confirm that these 
molecules interacted with the same molecular target on the cell 
surface, we also performed competition experiments for binding to 
Jurkat cells using an AF647-labeled Otter (Otter-AF647) and fluores-
cein isothiocyanate (FITC)-labeled 1 (c1-FITC) by flow cytometry. 
With the concentration of Otter-AF647 kept constant, increasing 
concentrations of c1-FITC resulted in an increase in the observed 
FITC signal (Figure 4c) and a concomitant decrease in the AF647 
signal (Figure 4d) demonstrating that these aptamers compete for 
binding. Competition was further confirmed by microscopy where 
both Otter and c1 were found to co-localize within the same cellular 
compartments (Supplementary Figure S13).
The facile synthesis of a small nuclease stabilized RNA which 
is readily taken up by many different cells paves the way for the 
development and enhancement of novel RNA-based transfection 
strategies. Using the minimized c1, we performed an additional set 
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of staining experiments using normal human primary bronchial 
epithelial cells (NHBECs). Similar experiments were performed 
in  parallel  using  two  immortalized  lung  cell  lines:  A549  cells, 
an adenocarcinoma of human alveolar basal epithelial cells, and 
HBEC, human bronchial epithelial cells immortalized by overex-
pression of telomerase. As shown in Figure 5, the minimized con-
structs bound to and were internalized by NHBECs to an extent 
similar to that observed for the transformed lines. Internalization 
into the primary NHBECs was further confirmed by treatment 
with endocytosis inhibitors as described above (Supplementary 
Figure S14).
To extend our observations for generalized c1 uptake to a wider 
range of cell lines and to primary cells in vivo, we used an estab-
lished model of intravaginal delivery to assess aptamer uptake in 
cells of the genital mucosa. Fluorescently-labeled aptamer c1, con-
trol aptamer (c36) or phosphate-buffered saline (PBS) (150 pmol 
each) were administered vaginally to mice. Analysis of vaginal 
tissue isolated 24 hours after aptamer application showed fluores-
cence deep into the lamina propria only following application of 
c1 (Figure 6a,b). No fluorescence was observed in tissues treated 
with c36 or PBS (Figure 6c,d).
dIscussIon
The need for a facile, robust, and effective means of delivering 
drugs or other molecular cargoes into cells led us to design a 
selection scheme for RNA molecules that could internalize into 
cells independent of transfection reagents or physical manip-
ulation.  Interestingly,  our  selections  against  two  very  differ-
ent cell lines, one a human cancer line and the other a mouse 
immortalized  islet  cell  line,  yielded  internalizing  RNAs  with 
strikingly similar sequential and structural properties. By com-
bining the core motif with different cargoes and modifications, 
we may have generated a universal nucleic acid delivery reagent, 
similar to the Tat peptide that has been used in hundreds of 
  scientific studies as well as in clinical trials.29 When the aptamer 
was applied to the vaginal mucosa of mice the observed stain-
ing and uptake patterns were similar to those seen following the 
administration of small interfering RNAs (siRNAs) using trans-
fection agents30,31 or following the administration of cholesterol-
  derivatized siRNAs.32
Just as the mechanism of uptake for Tat has been slowly elu-
cidated,33 it seems that c1 can be readily utilized by researchers 
even as the pathway of internalization is further explored. Thus 
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far, attempts by our labs to identify the molecular target for the 
selected  internalizing  RNA  motif  using  immunopreciptaion  as 
well  as  crosslinking  studies  have  proved  inconclusive.  Indeed, 
the blind nature of our internalization selection approach need 
not have even targeted a protein, a point we will further pursue. 
However, like Tat, the lack of this knowledge does not preclude 
the potential utility of this molecule. More broadly, by develop-
ing a protocol that selects functionally for internalization, we have 
opened the way to the direct development of cell- and organ-
specific reagents that can greatly change how small RNAs interact 
with intracellular targets.
MAterIAls And Methods
Cell  culture.  A431,  Bend3,  and  HeLa  cells  were  obtained  from  the 
American Tissue Culture Collection (ATTC, Manassas, VA) and cultured 
in Dulbecco’s modified Eagle medium (DMEM) (ATCC) supplemented 
with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA). LnCAP 
cells were also purchased from ATCC and were cultured in RPMI-1640 
(Invitrogen) supplemented with 10% FBS.
Min6B1 cells were a kind gift of Dr Jeffrey Pessin at the Diabetes 
Center at the Albert Einstein College of Medicine, New York, and were 
cultured  in  DMEM  supplemented  with  10%  FBS.  HBEC,  A549,  and 
primary NHBEC cells were a kind gift of Dr Simon Spivack at the Albert 
Einstein College of Medicine, New York and were cultured in F12 Kaighn’s 
medium supplemented with 10% FBS. HeLa-PSMAs cells were generated 
in our lab using a PSMA expression vector in which the open reading 
frame (positions −128 to 2,253) was inserted between the Kpn1 and Xba1 
of the EF1 promoter driven vector pEF6-V5HisA (Invitrogen).
All cells were grown at 37 °C with 5% CO2 and 99% humidity.
Aptamer libraries, aptamers, and oligonucleotides. All primers used for 
PCR as well the biotinylated oligonucleotides used for flow cytometry were 
purchased from IDT (Coralville, IA). All pools and minimized aptamers 
were synthesized in our lab on an Expedite 8909 DNA synthesizer (Applied 
Biosystems, Carlsbad, CA) using standard synthesis procedures. Unless noted 
otherwise, all reagents were purchased from Glen Research (Sterling, VA).
Libraries were synthesized such that N regions contained an equal 
probability of containing A, T, G, or C, as previously described.34 Following 
deprotection, libraries were gel purified by denaturing (7 mol/l urea) gel 
electrophoresis on an 8% polyacrylamide gel. The single-stranded DNA 
library was amplified by PCR to generate a double-stranded DNA bearing 
a T7 promoter and transcribed in vitro using the Y639F mutant of T7 
RNA polymerase35,36 or Durascribe kits and 2′-fluoro-pyrimidines. The 
RNA was purified on a denaturing (7 mol/l urea) 8% polyacrylamide gel.
Biotinylated,  minimized  aptamer  variants  were  chemically  syn-
thesized in our lab using 2′-fluoro-dC and 2′-fluoro-dU phosphoramidites 
(Metkinen, Kuusisto, Finland) bearing an inverted dT residue for added 
stability. Thiolated, minimized aptamer variants were synthesized using 
a thiol-modifier C6 S-S phosphoramidite. All aptamers were synthesized 
with  4,4′-dimethoxytrityl  on.  Following  deprotection,  aptamers  were 
purified  by  reversed  phase  high-performance  liquid  chromatography 
(HPLC) on a 10 × 50 mm Xbridge C18 column (Waters, Milford, MA) 
using a linear gradient of acetonitrile in 0.1 mol/l triethylammonium 
acetate at pH 7.0.
Thiolated aptamers were used to generate the AlexaFluor488 (A488)-
labeled  aptamer  used  for  in  vivo  microscopy  studies.  Labeling  was 
performed using AF488-C5-malemide as follows: 10 nmol of thiolated 
aptamer was reduced using 10 mmol/l tricarboxyethylphosphine in 100 μl 
of 0.1 mol/l triethylammonium acetate. Samples were heated at 70 °C for 
3 minutes followed by incubation at room temperature for 1 hour. The 
reduced aptamers were desalted using on a Biospin 6 column (Bio-Rad, 
Hercules, CA) into PBS supplemented with 50 mmol/l phosphate, pH 
7.5. To this, 10 μl of dimethyl sulfoxide (DMSO) was added containing 
50 nmol AF488-C5-malemide. Following an overnight reaction at 4 °C, 
the oligonucleotide was recovered by ethanol precipitation and desalted 
an additional time using a Biospin 6 column. Dye to aptamer ratios were 
determined at 260 and 488 nm and were typically ~1. The absence of free 
dye in the final product was confirmed by reversed phase HPLC.
Real-time PCR analysis of aptamer binding and internalization. The anti-
PSMA aptamer, A9,7 was used to proof internalization into cells. Approximately 
50,000 PSMA-positive LnCAP cells were plated per well in a 24-well plate 
and allowed to grow overnight such that cells would be at ~105 cells/well at 
assay time. The cells were washed in DPBS (Invitrogen) and treated with one 
of four conditions: 50 nmol/l anti-PSMA aptamer was added directly to the 
media on cells (RNA); cells were first treated for 10 minutes with 10 mmol/l 
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Figure 5  c1.min binds to primary cells as well as transformed lung 
cell lines. Phycoerythrin-labeled c1.min (red) was tested for binding to 
the transformed lung cell lines A549 and HBEC cells as well as normal 
human primary bronchial epithelial cells (NHBECs). A random RNA of a 
defined sequence (cntrl36, blue) served as a negative control. Untreated 
cells are shown in gray. The cell lines tested are as indicated. HBEC, 
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Az and 50 mmol/l dG to prevent endocytosis, then RNA was added to the 
media after washing (Az-dG); RNA was added to cells, and then cells were 
nuclease-treated with 0.02 U/μl Riboshredder (Epicentre, Madison, WI) to 
digest species bound to the cell surface (Rb); or cells were treated with Az-dG, 
washed and treated with RNA and nuclease-treated (Az-dG/Rb). Each treat-
ment was performed in triplicate. Total cell RNA from each of the treatments 
was extracted with Trizol (Invitrogen) following manufacturer’s protocols. 
For reverse transcription, 500 ng total cell RNA was incubated with 5 pmol 
aptamer-specific reverse primer (5′-TCGGGCGAGTCGTCTG-3′), 5 pmol 
pool-specific  primer  (5′-AAGCTTCGTCAAGTCTGCAGTGAA-3′),  and 
5 pmol  glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH)  reverse 
primer  (5′-GAAGGTGAAGGTCGGAGT-3′)  in  First  Strand  Buffer.  The 
solution was heated to 70 °C for 3 minutes and then cooled on ice. A solu-
tion of 50 nmol dithiothreitol, 5 pmol each deoxynucleotide triphosphate 
and 50 U Superscript III reverse transcriptase (Invitrogen) was added to the 
primer mix for a final total volume of 10 μl and incubated at 50 °C for 1 hour 
followed by an inactivation step at 70 °C for 15 minutes.
Real-time PCR was performed using a 7300 Real Time PCR System (Applied 
Biosystems). PCR reactions consisted of 1 μl of reverse transcription reaction, 
12.5 μl SYBR Green Mastermix (Applied Biosystems), 10 pmol target-specific 
reverse primer, and 10 pmol target-specific forward primer in a total volume 
of 25 μl. Separate reactions were performed to amplify the aptamer (forward 
primer: 5′-TTCTAATACGACTCACTATAGGGAGGACGATGCGG-3′), or 
GAPDH (forward primer: 5′-TCGACCGTGTGCGCTCGCTG-3′). Cycling 
conditions started with an initial denaturation step at 95 °C for 10 minutes 
followed by 40 cycles of 95 °C for 30 seconds, 50 °C for 30 seconds, and 72 °C 
for 1 minute. A final cycle of 95 °C for 15 seconds, 60 °C for 30 seconds, and 
95 °C for 15 seconds was used to generate dissociation curves to check the 
integrity of the products. The levels of each species were calculated by the 
ΔΔCt method by taking the difference in Ct between each sample and cells 
control and then normalizing to GAPDH levels for each sample.
Doped-A9 selection. The sequence of the doped-A9 library used for the 
selection was, 5′-GGGAGGACGATGCGGACCGAAAAAGACCTGACT 
TCTATACTAAGUCUACGTTCCCAGACGACTCGCCCGATTGAA 
TTAAATGCCCGCCATCACCAG-3′, where the underlined residues were 
doped to a level of 30%. Library preparation was performed as described 
above.
The  internalization  selection  was  performed  using  HeLa-PSMA 
cells. For each round, ~105  adherent  cells  were  incubated  in  300 μl 
of DMEM supplemented with 10% FBS and 1 mg/ml transfer RNA 
(tRNA)  and  ssDNA  (Sigma,  St  Louis,  MO)  as  blocking  agents.  The 
first round of selection used 30 μg of the A9 doped pool encompassing 
~1013 unique variants. Subsequent rounds were performed using 3 μg 
of RNA. For each round of selection, the pool was combined with a 
1.5-fold molar excess of reverse primer bearing a 5′ fluorescein dye. 
The mixture was denatured at 70 °C for 3 minutes and allowed to refold 
at room temperature for at least 15 minutes before addition to cells. 
RNA was added to the blocked cells and incubated for 1 hour at 37 °C. 
Following  incubation,  the  cells  were  washed  three  times  with  1 ml 
HBSS (Hank’s buffered saline solution; Invitrogen) containing 0.1% Az, 
once with 1 ml cold 200 mmol/l glycine and 150 mmol/l NaCl at pH 4, 
and three more times with HBSS. Cells were lifted with 500 μl trypsin-
EDTA (Mediatech, Manassas, VA) containing 0.1% Az, removed from 
the plate, washed with 1 ml HBSS and resuspended in 100 μl HBSS 
containing 5 μl Riboshredder RNAse cocktail (Epicentre). Following a 
15 minute incubation at room temperature, the cells were washed an 
additional three times with 1 ml of HBSS. Cells were lysed, and RNA 
was  recovered  using  Trizol  extraction  according  to  manufacturer’s 
protocol. Recovered RNA was reverse-transcribed and amplified by 
PCR. Double-stranded DNA was ethanol precipitated and transcribed 
back into RNA. The progress of the selection was monitored by flow 
cytometry as described below.
ab
cd
Figure 6  efficient uptake of c1 aptamers applied to the vaginal mucosa. One hundred and fifty pmol of an (a) AlexaFluor 488-labeled c1 aptamer 
or (c) control aptamer (c36) were applied to the vaginal mucosa. Vaginal sections were obtained after 24 hours. (b) Area of magnification ×2.5 high-
lighted in box in a. (d) Tissue section from an untreated mouse. Yellow arrowhead = luminal edge of epithelium. EP, epithelium; LP, lamina propia.Molecular Therapy  vol. 20 no. 3 mar. 2012  623
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Following the third round of selection, the pool was cloned using the 
TOPO TA kit (Invitrogen) and 19 clones were sequenced, transcribed, 
and assayed by flow cytometry for their ability to bind to wild-type HeLa 
cells or HeLa-PSMA cells.
HeLa cell internalization selection. The sequence of the N62 library used for 
selection against HeLa cells was: 5′-GGCGCTCCGACCTTAGTCTCTG-
N62-GAACCGTGTAGCACAGCAGA-3′.  Library  preparation  was  per-
formed  as  described  above.  Each  round  of  selection  employed  1 nmol 
RNA,  which  corresponds  to  a  starting  library  size  of  ~1014.  Thermally 
equilibrated RNA was added to 5 ml of media in a T-75 flask containing   
~6 × 106 HeLa cells and incubated for 30 minutes at 37 °C with 5% CO2. 
Cells were then washed with 10 ml DPBS three times and lifted with trypsin. 
The cells were suspended in 5 ml of DMEM supplemented with 10% FBS 
and recovered by centrifugation at 200g for 5 minutes. The cell pellets were 
each resuspended in 100 μl DPBS, combined, pelleted, and washed three 
more times in 1 ml DPBS. Total cell RNA was recovered using the mirVana 
Kit (Invitrogen) according to manufacturer’s protocol, and eluted in 40 μl 
of elution buffer; 20 μl of the isolated RNA was used in a 40 μl reverse tran-
scription reaction using SuperScript III reverse transcriptase (Invitrogen) 
and the N62 reverse primer according to manufacturer’s protocol. Following 
PCR amplification, the double-stranded DNA was ethanol precipitated, 
transcribed back into RNA and purified as described above. After Round 2,   
the cells were washed four times as described above, then resuspended in 
100 μl DPBS containing 5 mmol/l MgCl2 and 10 μl Riboshredder RNase. 
The reaction was allowed to proceed for 15 minutes at room temperature 
after which the cells were washed five times in 1 ml DPBS and resuspended 
in 100 μl DPBS supplemented with 10 μl of RNase Out (Invitrogen). The 
mixture was left at room temperature for 2 minutes after which the cells 
were pelleted, and the RNA was isolated as described above.
Min6B1  cell  internalization  selection. The sequence of the N50 library used for 
selection against Min6B1 cells was: 5′-GGGAGGTGAATGGTTCTACGAT-
N50-TTACATGCGAGATGACCACGTAATTGAATTAAATGCCCGCC
ATGACCAG-3′. Library preparation was performed as described above. 
For the first round of selection, Min6B1 cells were grown as an adherent 
monolayer and cultured in a 6-well plate to about 90% confluence (~106 
cells). Cells were blocked with 0.1 μg/μl tRNA and ssDNA in 1 ml DMEM 
supplemented with 10% FBS for 30 minutes at 37 °C before the addition 
of  1.2 nmol  of  thermally  equilibrated  RNA  library  (~1014  sequences). 
Following a 1 hour incubation at 37 °C, the cells were washed three times 
with 1 ml HBSS to remove unbound RNA, and then cells were lifted by the 
addition of trypsin in the presence of 10 mmol/l EDTA for 20 minutes at 
37 °C. Cells were recovered by centrifugation and washed three times with 
1 ml HBSS. Total cell RNA was Trizol extracted, according to the manu-
facturer’s protocol. Recovered RNA was reverse-transcribed using MMLV 
reverse transcriptase (Invitrogen) and the N50 reverse primer according 
to the manufacturer’s protocol. Following PCR amplification, the double-
stranded DNA was ethanol precipitated and transcribed back into RNA 
and purified as described above. For Rounds 7–10, an RNase treatment step 
followed trypsinization. Cells were incubated in 500 μl of HBSS containing 
0.1% azide and 5 μl of RNAse RiboShredder (Epicentre) at room tempera-
ture for 20 minutes. Cells were then washed three times with 1 ml HBSS 
containing 0.1% azide, and total RNA was recovered by Trizol extraction. 
Rounds 11 and 12 were performed exactly as previously described, except 
that freshly isolated islets were used as the target cells.
Preparation of adult mouse islets. Pancreatic islets were isolated from 5- to 
8-week old male BALB/c mice. The pancreas was first distended by intra-
ductal injection of collagenase solution (1 mg/ml in HBSS). Collagenase 
digestion was performed at 37 °C for 13 minutes. Subsequently, the pan-
creas was excised, and the digestion was quenched by addition of cold 
HBSS. The islets suspension was washed three times with cold HBSS, and 
islets were separated by centrifugation on a Histopaque discontinuous gra-
dient for 20 minutes at 1700g at 4 °C. Islets were picked and counted under 
an inverted microscope. The islets were cultured in 100 mm dishes at 37 °C 
in humidified 5% CO2 in RPMI-1640 medium supplemented with 10% 
FBS and 1× penicillin/streptomycin solution (Invitrogen) for 5 days.
Binding  assay  by  flow  cytometric  analysis.  Aptamer  binding  and 
uptake was assessed by flow cytometry. Rounds from each selection or 
isolated  clones  were  first  hybridized  to  a  biotinylated  oligonucleotide 
(B-CTGGTCATGGCGGGCATTTAATTC) which was complementary to 
the 3′ end of the library. The population or individual aptamer was incu-
bated at 1 μmol/l with 1.5 μmol/l biotinylated oligonucleotide in DPBS 
heated to 70 °C for 3 minutes and then allowed to cool on the bench top for 
15 minutes. Following hybridization, the aptamers were complexed with 
1.5 μmol/l streptavidin-R-phycoerythrin (Prozyme, Hayward, CA) for an 
additional 15 minutes. For assays performed with biotinylated minimized 
aptamers, following thermal equilibration, 1 μmol/l aptamer was incubated 
with 1.5 μmol/l streptavidin-R-phycoerythrin and incubated for 15 min-
utes before addition to cells.
For the assay, cells were first blocked with 0.1 μg/μl tRNA and ssDNA 
in DMEM supplemented with 10% FBS for 30 minutes at 37 °C. Aptamer 
complexes were added to cells at a final concentration of 50–100 nmol/l 
(as indicated) for 30–60 minutes (as indicated) at 37 °C and 5% CO2. 
Cells were then washed three times with DPBS, trypsinized and washed 
with fluorescence-activated cell sorting (FACS) buffer (HBSS, 1% bovine 
serum  albumin,  0.1%  Az).  Samples  designated  to  test  internalization 
were  treated  with  Riboshredder  cocktail  as  described  above  for  the 
selection. After incubation, cells were washed twice with FACS buffer and 
resuspended in FACS buffer with 7-aminoactinomycin D stain (7AAD) 
to exclude dead cells in the analysis. Flow cytometry was performed on 
a FACScan or FACScalibur flow cytometer (Becton Dickinson, Franklin 
Lakes, NJ).
Microscopy. For microscopic analysis of Min6B1, Hela, and Bend3 cells, 
cells were grown as adherent monolayers in Labtek 8-chamber glass slides 
systems (Thermo Scientific, Rochester, NY). Thirty minutes before aptamer 
treatment, cells were blocked with 0.1 μg/μl tRNA and ssDNA in DMEM 
supplemented with 10% FBS at 37 °C. The blocked cells were then incu-
bated with 100 nmol/l 5′-biotinylated c1 or 5′-biotinylated control aptamer 
conjugated to streptavidin-R-phycoerythrin (Prozyme) at 37 °C for 1 hour. 
Cells were then washed three times with PBS and fixed with 4% formal-
dehyde solution for 15 minutes at room temperature. The fixed cells were 
washed three times with PBS and mounted in mounting media (0.1 mol/l 
propylgalate, 50% glycerol in PBS) containing 1 μg/ml 4′-6-diamidino-2-
phenylindole (DAPI). Cells were also assayed without fixation and visual-
ized on a Zeiss Axio Observer fluorescence microscope (Thornwood, NY).
Competition binding assay by flow cytometry analysis. Approximately 
5  ×  104  Jurkat  cells  were  blocked  with  0.1 μg/μl  tRNA  and  ssDNA  in 
DMEM supplemented with 10% FBS for 30 minutes at 37 °C. Cells were 
then incubated with 400 nmol/l 5′-biotinylated Otter aptamer conjugated 
to AlexaFluor-647-labeled streptavidin (Invitrogen) and increasing con-
centrations (0, 0.2, 0.4, 0.8, 2, and 4 μmol/l) of either 5′-biotinylated c1 or 
5′-biotinylated Otter conjugated to FITC-labeled streptavidin (Invitrogen) 
at 37 °C for 1 hour. Cells were washed with FACS buffer and analyzed by 
flow cytometry; 7AAD was used to exclude the presence of dead cells.
Endocytosis inhibition. Jurkat, HEK EBNA 293, or NHBE cells were incu-
bated with either 10 μmol/l phenylarsine oxide or 100 μmol/l indomethacin 
in RPMI-1640 media at 37 °C during 30 minutes. Cells were then blocked 
with  RPMI-1640  medium  supplemented  with  10%  FBS  and  0.1 μg/μl 
tRNA and ssDNA for 30 minutes at 37 °C; 100 nmol/l 5′-biotinylated c1 
or  5′-biotinylated  control  aptamer  conjugated  to  streptavidin-R-phyco-
erythrin (Prozyme) was added to the media and incubated at 37 °C for   
1 hour. RNase treated samples were further incubated with 10 μl of RNase 
Riboshredder  (Epicentre)  in  RPMI-1640  supplemented  with  10%  FBS. 
Cells were washed with HBSS and analyzed by flow cytometry.624  www.moleculartherapy.org  vol. 20 no. 3 mar. 2012     
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Vaginal  uptake  experiments.  C57BL/6  mice  (Taconic,  Hudson,  NY) 
were  subcutaneously  injected  with  2 mg  medroxyprogesterone  acetate 
(Greenstone, Peapack, NJ) to maintain them in diestrus. One week later, 
150 pmol c1 aptamer or control c36 aptamer labeled with AlexaFluor A488 
were  administered  intravaginally  in  15 μl  of  DPBS.  Twenty-four  hours 
later, vaginal tissue was dissected, placed in Tissue-Tek optimal cutting 
temperature compound (Sakura Finetek, Torrance, CA) and snap-frozen 
in liquid nitrogen; 10 μm sections were fixed in acetone and mounted. 
Images were acquired by fluorescence microscopy (Leica SP5) using Leica 
LAS-AF software (Leica Microsystems, Buffalo Grove, IL) and analyzed by 
ImageJ (NIH, Bethesda, MD). All animal studies have been approved by 
the Albert Einstein College of Medicine institutional review board.
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